TY - JOUR AU - Mok, T. S. AU - Wu, Y. -. L. AU - Thongprasert, S. AU - Yang, C. -. H. AU - Chu, D. -. T. AU - Saijo, N. PY - 2009 DA - 2009// TI - Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0810699 DO - 10.1056/NEJMoa0810699 ID - Mok2009 ER - TY - JOUR AU - Zhou, C. AU - Wu, Y. -. L. AU - Chen, G. AU - Feng, J. AU - Liu, X. -. Q. AU - Wang, C. PY - 2011 DA - 2011// TI - Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study JO - Lancet Oncol VL - 12 UR - https://doi.org/10.1016/S1470-2045(11)70184-X DO - 10.1016/S1470-2045(11)70184-X ID - Zhou2011 ER - TY - JOUR AU - Sequist, L. V. AU - Yang, J. C. AU - Yamamoto, N. AU - O’Byrne, K. AU - Hirsh, V. AU - Mok, T. PY - 2013 DA - 2013// TI - Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.44.2806 DO - 10.1200/JCO.2012.44.2806 ID - Sequist2013 ER - TY - JOUR AU - Wu, Y. -. L. AU - Zhou, C. AU - Hu, C. -. P. AU - Feng, J. AU - Lu, S. AU - Huang, Y. PY - 2014 DA - 2014// TI - Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-lung 6): an open-label, randomised phase 3 trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(13)70604-1 DO - 10.1016/S1470-2045(13)70604-1 ID - Wu2014 ER - TY - JOUR AU - Beau-Faller, M. AU - Prim, N. AU - Ruppert, A. -. M. AU - Nanni-Metéllus, I. AU - Lacave, R. AU - Lacroix, L. PY - 2014 DA - 2014// TI - Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdt418 DO - 10.1093/annonc/mdt418 ID - Beau-Faller2014 ER - TY - JOUR AU - Pas, T. AU - Toffalorio, F. AU - Manzotti, M. AU - Fumagalli, C. AU - Spitaleri, G. AU - Catania, C. PY - 2011 DA - 2011// TI - Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations JO - J Thorac Oncol VL - 6 UR - https://doi.org/10.1097/JTO.0b013e318227e8c6 DO - 10.1097/JTO.0b013e318227e8c6 ID - Pas2011 ER - TY - JOUR AU - Watanabe, S. AU - Minegishi, Y. AU - Yoshizawa, H. AU - Maemondo, M. AU - Inoue, A. AU - Sugawara, S. PY - 2014 DA - 2014// TI - Effectiveness of gefitinib against non–small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q JO - J Thorac Oncol VL - 9 UR - https://doi.org/10.1097/JTO.0000000000000048 DO - 10.1097/JTO.0000000000000048 ID - Watanabe2014 ER - TY - JOUR AU - Solca, F. AU - Dahl, G. AU - Zoephel, A. AU - Bader, G. AU - Sanderson, M. AU - Klein, C. PY - 2012 DA - 2012// TI - Target binding properties and cellular activity of afatinib (BIBW2992), an irreversible ErbB family blocker JO - J Pharmacol Exp Ther VL - 343 UR - https://doi.org/10.1124/jpet.112.197756 DO - 10.1124/jpet.112.197756 ID - Solca2012 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. AU - Schwartz, L. H. AU - Sargent, D. AU - Ford, R. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - STD TI - National Cancer Institute Common terminology criteria for adverse events (CTCAE), Version 4.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc. htm. Accessed June 2020. UR - https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.%20htm ID - ref10 ER - TY - JOUR AU - Urata, Y. AU - Katakami, N. AU - Morita, S. AU - Kaji, R. AU - Yoshioka, H. AU - Seto, T. PY - 2016 DA - 2016// TI - Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.63.4154 DO - 10.1200/JCO.2015.63.4154 ID - Urata2016 ER - TY - JOUR AU - Park, K. AU - Tan, E. -. H. AU - O’Byrne, K. AU - Zhang, L. AU - Boyer, M. AU - Mok, T. PY - 2016 DA - 2016// TI - Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-lung 7): a phase 2B, open-label, randomised controlled trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30033-X DO - 10.1016/S1470-2045(16)30033-X ID - Park2016 ER - TY - JOUR AU - Kim, Y. AU - Lee, S. -. H. AU - Ahn, J. S. AU - Ahn, M. -. J. AU - Park, K. AU - Sun, J. -. M. PY - 2019 DA - 2019// TI - Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib JO - Cancer Res Treat VL - 51 UR - https://doi.org/10.4143/crt.2018.117 DO - 10.4143/crt.2018.117 ID - Kim2019 ER - TY - JOUR AU - Yasuda, H. AU - Park, E. AU - Yun, C. -. H. AU - Sng, N. J. AU - Lucena-Araujo, A. R. AU - Yeo, W. -. L. PY - 2013 DA - 2013// TI - Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer JO - Sci Transl Med VL - 5 UR - https://doi.org/10.1126/scitranslmed.3007205 DO - 10.1126/scitranslmed.3007205 ID - Yasuda2013 ER - TY - JOUR AU - Naidoo, J. AU - Sima, C. S. AU - Rodriguez, K. AU - Busby, N. AU - Nafa, K. AU - Ladanyi, M. PY - 2015 DA - 2015// TI - Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib JO - Cancer VL - 121 UR - https://doi.org/10.1002/cncr.29493 DO - 10.1002/cncr.29493 ID - Naidoo2015 ER - TY - JOUR AU - Yu, H. A. AU - Arcila, M. E. AU - Hellmann, M. D. AU - Kris, M. G. AU - Ladanyi, M. AU - Riely, G. J. PY - 2014 DA - 2014// TI - Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdt573 DO - 10.1093/annonc/mdt573 ID - Yu2014 ER - TY - JOUR AU - Castellanos, E. AU - Feld, E. AU - Horn, L. PY - 2017 DA - 2017// TI - Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non–small cell lung cancer JO - J Thorac Oncol VL - 12 UR - https://doi.org/10.1016/j.jtho.2016.12.014 DO - 10.1016/j.jtho.2016.12.014 ID - Castellanos2017 ER - TY - JOUR AU - Yang, J. C. AU - Sequist, L. V. AU - Geater, S. L. AU - Tsai, C. -. M. AU - Mok, T. S. K. AU - Schuler, M. PY - 2015 DA - 2015// TI - Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-lung 2, LUX-lung 3, and LUX-lung 6 JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00026-1 DO - 10.1016/S1470-2045(15)00026-1 ID - Yang2015 ER - TY - JOUR AU - Chiu, C. -. H. AU - Yang, C. -. T. AU - Shih, J. -. Y. AU - Huang, M. -. S. AU - Su, W. -. C. AU - Lai, R. -. S. PY - 2015 DA - 2015// TI - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations JO - J Thorac Oncol VL - 10 UR - https://doi.org/10.1097/JTO.0000000000000504 DO - 10.1097/JTO.0000000000000504 ID - Chiu2015 ER - TY - JOUR AU - Tu, H. -. Y. AU - Ke, E. -. E. AU - Yang, J. -. J. AU - Sun, Y. -. L. AU - Yan, H. -. H. AU - Zheng, M. -. Y. PY - 2017 DA - 2017// TI - A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer JO - Lung Cancer VL - 114 UR - https://doi.org/10.1016/j.lungcan.2017.11.005 DO - 10.1016/j.lungcan.2017.11.005 ID - Tu2017 ER - TY - JOUR AU - Shen, Y. -. C. AU - Tseng, G. -. C. AU - Tu, C. -. Y. AU - Chen, W. -. C. AU - Liao, W. -. C. AU - Chen, W. -. C. PY - 2017 DA - 2017// TI - Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations JO - Lung Cancer VL - 110 UR - https://doi.org/10.1016/j.lungcan.2017.06.007 DO - 10.1016/j.lungcan.2017.06.007 ID - Shen2017 ER - TY - JOUR AU - Chang, L. -. C. AU - Lim, C. -. K. AU - Chang, L. -. Y. AU - Chen, K. -. Y. AU - Shih, J. -. Y. AU - Yu, C. -. J. PY - 2019 DA - 2019// TI - Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors JO - Eur J Cancer VL - 119 UR - https://doi.org/10.1016/j.ejca.2019.06.025 DO - 10.1016/j.ejca.2019.06.025 ID - Chang2019 ER - TY - JOUR AU - Xu, H. AU - Li, W. AU - Yang, G. AU - Li, J. AU - Yang, L. AU - Xu, F. PY - 2020 DA - 2020// TI - Heterogeneous response to first-generation tyrosine kinase inhibitors in non-small-cell lung cancers with different EGFR exon 19 mutations JO - Target Oncol VL - 15 UR - https://doi.org/10.1007/s11523-020-00722-0 DO - 10.1007/s11523-020-00722-0 ID - Xu2020 ER - TY - BOOK PY - 2020 DA - 2020// TI - NCCN clinical practice guidelines in oncology. Non-Small Cell Lung Cancer. Version 8 ID - ref24 ER -